Jakafi

Argus said in a note that it sees bullish growth outlook for Incyte Corporation (NASDAQ: INCY) given its solid late-stage pipeline and key strategic R&D partnerships with companies such as Merck & Co., Inc. (NYSE: MRK), Novartis AG (ADR)(NYSE: NVS), Bristol-Myers Squibb Co (NYSE: BMY)...

Thomas Yip of FBR commented in a note on Monday that shares of Geron Corporation (NASDAQ: GERN) are undervalued. Geron's imetelstat's pilot study will be presented during the upcoming American Society of Hematology (ASH) meeting in early December. Yip stated the presentation could "attract...